M. Morrow

发表

CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement

N. Brewis, Miguel Gaspar, J. Pravin, 2020, Cancer Immunology Research.

A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist

L. Young, C. Leow, R. Wilkinson, 2017, Clinical Cancer Research.

CBFbeta is critical for AML1-ETO and TEL-AML1 activity.

L. Roudaia, J. Bushweller, N. Speck, 2009, Blood.

TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL

D. Kioussis, H. Brady, M. Morrow, 2007, Oncogene.

Radiation Therapy Induces an Adaptive Upregulation of PD-L1 on Tumor Cells Which May Limit the Efficacy of the Anti-Tumor Immune Response But Can Be Circumvented by Anti-PD-L1

T. Illidge, R. Wilkinson, S. Dovedi, 2014 .

TEL-AML1 promotes development of specific hematopoietic lineages consistent with preleukemic activity.

D. Kioussis, H. Brady, M. Morrow, 2004, Blood.

Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model

R. Wilkinson, N. Luheshi, A. Lewis, 2016, Oncotarget.

Design and efficacy of a monovalent bispecific PD-1/CTLA-4 antibody that enhances CTLA-4 blockade on PD-1+ activated T cells.

Daniel J. Freeman, Des C. Jones, B. Tran, 2021, Cancer discovery.

Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer

J. Hood, R. Wilkinson, N. Luheshi, 2021, mAbs.

Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody

V. Bedian, R. Wilkinson, I. Foltz, 2015, Cancer Immunology Research.

Novel NUDT2 variant causes intellectual disability and polyneuropathy

S. Nelson, R. Person, J. Martinez-Agosto, 2020, Annals of clinical and translational neurology.

FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity

L. Young, Sarah Batey, N. Brewis, 2020, Clinical Cancer Research.

CBF (cid:1) is critical for AML1-ETO and TEL-AML1 activity

L. Roudaia, J. Bushweller, N. Speck, 2009 .

Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.

I. Stratford, T. Illidge, R. Wilkinson, 2014, Cancer research.

MYT1L-associated neurodevelopmental disorder: description of 40 new cases and literature review of clinical and molecular aspects

W. Chung, A. Munnich, B. Menten, 2021, Human Genetics.

Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade

R. Emerson, M. Vignali, H. Robins, 2017, Clinical Cancer Research.

ERG is a megakaryocytic oncogene.

N. Sebire, S. Izraeli, J. de Boer, 2009, Cancer research.

Enhanced MAPK1 Function Causes a Neurodevelopmental Disorder within the RASopathy Clinical Spectrum.

W. Chung, Q. Waisfisz, B. Gelb, 2020, American journal of human genetics.

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

Simon J. Dovedi, D. Greenawalt, Dennis Wang, 2016, Cancer Immunology Research.

Continuous MLL-ENL expression is necessary to establish a "Hox Code" and maintain immortalization of hematopoietic progenitor cells.

D. Grier, D. Kioussis, D. Moulding, 2005, Cancer research.

D. Horn, M. Holtgrewe, K. Kosaki, 2021, Genetics in Medicine.

Hsa-mir-125b-2 is highly expressed in childhood ETV6/RUNX1 (TEL/AML1) leukemias and confers survival advantage to growth inhibitory signals independent of p53

Noam Shomron, Arndt Borkhardt, Owen Williams, 2009, Leukemia.

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma

T. Schumacher, C. Blank, J. Gadiot, 2012, Oncoimmunology.

Abstract 2719: Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+ T-cell activation and modulates the tumor microenvironment to promote antitumor immune responses

L. Young, N. Brewis, J. Doody, 2018, Immunology.

Genetic Counseling at the Intersection of Clinical Genetics and Informatics

M. Morrow, Christine Munro, A. McCarty, 2019, Health Informatics.

FIBCD1 is a Conserved Receptor for Chondroitin Sulphate Proteoglycans of the Brain Extracellular Matrix and a Candidate Gene for a Complex Neurodevelopmental Disorder

N. Perrimon, M. Burmeister, J. Penninger, 2021 .

The RAC specific guanine nucleotide exchange factor Asef functions downstream from TEL-AML1 to promote leukaemic transformation.

M. Hubank, N. Sebire, M. Morrow, 2010, Leukemia research.

Abstract LB-158: MEDI4736: Delivering effective blockade of immunosupression to enhance tumour rejection: Monoclonal antibody discovery and preclinical development

V. Bedian, Suping Wang, M. Mccourt, 2011 .